Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 34
Filtrar
1.
Inflamm Bowel Dis ; 2024 Aug 03.
Artículo en Inglés | MEDLINE | ID: mdl-39096520

RESUMEN

BACKGROUND: Genetic discovery in very early-onset inflammatory bowel disease (VEO-IBD) can elucidate not only the origins of VEO-IBD, but also later-onset inflammatory bowel disease. We aimed to investigate the polygenic origins of VEO-IBD in a cohort with a high proportion of Hispanic patients. METHODS: Patients with VEO-IBD who underwent whole exome sequencing at our center were included. Genes were categorized as genes of interest (GOIs) (129 genes previously described to be associated with VEO-IBD) or non-GOIs. VEO-IBD "susceptibility" single nucleotide variants (SNVs) were identified through enrichment compared with gnomAD (Genome Aggregation Database) and ALFA (Allele Frequency Aggregator) and were scored by Combined Annotation Dependent Depletion for deleteriousness. Gene networks carrying susceptibility SNVs were created. Myosin 5b immunofluorescence was also studied. RESULTS: Fifty-six patients met inclusion criteria, and 32.1% identified as Hispanic. Monogenic disease was infrequent (8.9%). Significant enrichment of GOI susceptibility SNVs was observed, notably in MYO5B, especially in Hispanics. MEFV, TNFAIP3, SH3TC2, and NCF2 were also central participants in the GOI networks. Myosin 5b immunofluorescence in colonic mucosa was significantly reduced in those with MYO5B susceptibility SNVs compared with control subjects. Seven genes (ESRRA, HLA-DQ1, RETSAT, PABPC1, PARP4, CCDC102A, and SUSD2) were central participants in the non-GOI networks. CONCLUSIONS: Our results support the polygenic nature of VEO-IBD, in which key participants, like MYO5B, were identified through network analytics. Rare variant load within susceptibility genes may be relevant not only for the genetic origins of inflammatory bowel disease, but also for the age of disease onset. Our findings could guide future work in precision medicine.


We used a network tool to determine how multiple genes might play a combined role in the development of inflammatory bowel disease and identified key participants in this network, such as MYO5B.

3.
Neural Netw ; 169: 555-571, 2024 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-37952391

RESUMEN

Deep neural networks have achieved outstanding performance in computer vision tasks. Convolutional Neural Networks (CNNs) typically operate in the spatial domain with raw images, but in practice, images are usually stored and transmitted in their compressed representation where JPEG is one of the most widely used encoder. Also, these networks are computationally intensive and slow. This paper proposes performing the learning and inference processes in the compressed domain in order to reduce the computational complexity and improve the speed of popular CNNs. For this purpose, a novel graph-based frequency channel selection method is proposed to identify and select the most important frequency channels. The computational complexity is reduced by retaining the important frequency components and discarding the insignificant ones as well as eliminating the unnecessary layers of the network. Experimental results show that the modified ResNet-50 operating in the compressed domain is up to 70% faster than the spatial-based traditional ResNet-50 while resulting in similar classification accuracy. Moreover, this paper proposes a preprocessing step with partial encoding to improve the resilience to distortions caused by low-quality encoded images. Finally, we show that training a network with highly compressed data can achieve a good classification accuracy with up to 93% reduction in the storage requirements of the training data.


Asunto(s)
Redes Neurales de la Computación
4.
J Pediatr Gastroenterol Nutr ; 77(6): 748-752, 2023 12 01.
Artículo en Inglés | MEDLINE | ID: mdl-37229767

RESUMEN

NOD2/CARD15 was the first susceptibility gene recognized for adult-onset Crohn's (or Crohn) disease (CD). Recessive inheritance of NOD2 polymorphisms has been implicated as a mechanistic driver of pediatric-onset CD. In patients with very early-onset inflammatory bowel disease (VEO-IBD), however, the clinical relevance of NOD2 polymorphisms has not been fully established. Ten VEO-IBD patients with NOD2 polymorphisms ( NOD2 +) were compared to 16 VEO-IBD patients without genetic variants in NOD2 or any other VEO-IBD susceptibility genes ( NOD2 -). The majority of NOD2 + patients exhibited a CD-like phenotype (90%), linear growth impairment (90%), and arthropathy (60%), all of which were significantly more common than in the NOD2 - group ( P = 0.037, P = 0.004, P = 0.026, respectively). We propose that the presence of NOD2 polymorphisms in patients with VEO-IBD might confer a CD-like phenotype, linear growth impairment, and arthropathy. These findings should be validated in larger cohorts and may guide precision medicine for patients with VEO-IBD in the future.


Asunto(s)
Colitis Ulcerosa , Enfermedad de Crohn , Artropatías , Adulto , Niño , Humanos , Enfermedad de Crohn/genética , Colitis Ulcerosa/genética , Predisposición Genética a la Enfermedad , Proteína Adaptadora de Señalización NOD2/genética , Edad de Inicio , Fenotipo , Mutación
5.
JPGN Rep ; 4(1): e276, 2023 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-36915867

RESUMEN

Vedolizumab is an anti-α4ß7 integrin antibody that has been used successfully in the treatment of adult-onset inflammatory bowel diseases (IBDs: Crohn disease [CD] and ulcerative colitis [UC]). Its off-label use in the pediatric IBD (PIBD) population is increasing, but knowledge on durability beyond 6 months of treatment is limited. Methods: A real-life, single-center, retrospective study of PIBD patients treated with vedolizumab was performed. Data on demographics, prior and concomitant treatments, and disease activity were obtained at 14 weeks, 26 weeks, 1 year, and 2 years of therapy. Primary outcome was corticosteroid- and other biologic-free remission (based on pediatric ulcerative colitis activity index [PUCAI]). Results: Thirty-nine patients were studied. By 1 year, 65% of CD and 68% of UC patients continued on vedolizumab therapy. Corticosteroid- and other biologic-free remission was 29% in CD and 16% in UC. By 2 years, 36% of CD and 47% of UC patients continued therapy. Corticosteroid- and other biologic-free remission was 21% in CD and 40% in UC. By 2 years, 80% of CD and 100% of UC patients were on intensified treatment regimen compared to the manufacturer guidance. Nine patients (23%) required surgical intervention within 26 months of starting vedolizumab indicating the severity of IBD in this cohort. Conclusions: Vedolizumab is a useful therapeutic modality in PIBD patients refractory to anti-TNF therapy, although with declining effectiveness by 2 years. Intensified treatment regimens are associated with long-term durability. Larger prospective trials in children are warranted.

6.
JPGN Rep ; 3(4): e272, 2022 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-36406468
7.
Ann Clin Lab Sci ; 52(5): 796-801, 2022 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-36261187

RESUMEN

OBJECTIVE: The FDA approved adalimumab, an anti-tumor necrosis factor alpha agent, for the treatment of moderate to severe pediatric ulcerative colitis (UC) in February 2021. There are no real-world publications, however, on adalimumab as the first-line biologic in pediatric UC, a form of chronic inflammatory bowel disease (IBD). METHODS: A retrospective review was conducted to characterize the clinical courses of nine patients with moderate to severe pediatric UC who received adalimumab as their first biologic and had documented drug monitoring trough levels. RESULTS: Seven of the nine patients, or 78%, were switched from adalimumab to another therapy due to continued symptoms or steroid-dependence at an average of 5 months from initiation. Six of these seven patients, or 86%, had adalimumab drug trough levels in the consensus therapeutic range. Three patients were successfully switched to infliximab. CONCLUSIONS: Both the Crohn's disease-based dosing and the new FDA-approved pediatric UC dosing of adalimumab were ineffective in inducing remission in the majority of patients in our case series. This study indicates that further real-world observations are needed to optimize and position adalimumab in the treatment paradigm of moderate to severe pediatric UC.


Asunto(s)
Productos Biológicos , Colitis Ulcerosa , Humanos , Niño , Infliximab/uso terapéutico , Adalimumab/uso terapéutico , Colitis Ulcerosa/tratamiento farmacológico , Productos Biológicos/uso terapéutico
8.
IEEE Trans Image Process ; 31: 5856-5868, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-36054395

RESUMEN

Although deep neural networks (DNNs) have been shown to be susceptible to image-agnostic adversarial attacks on natural image classification problems, the effects of such attacks on DNN-based texture recognition have yet to be explored. As part of our work, we find that limiting the perturbation's lp norm in the spatial domain may not be a suitable way to restrict the perceptibility of universal adversarial perturbations for texture images. Based on the fact that human perception is affected by local visual frequency characteristics, we propose a frequency-tuned universal attack method to compute universal perturbations in the frequency domain. Our experiments indicate that our proposed method can produce less perceptible perturbations yet with a similar or higher white-box fooling rates on various DNN texture classifiers and texture datasets as compared to existing universal attack techniques. We also demonstrate that our approach can improve the attack robustness against defended models as well as the cross-dataset transferability for texture recognition problems.


Asunto(s)
Redes Neurales de la Computación , Humanos
9.
JIMD Rep ; 63(4): 309-315, 2022 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-35822097

RESUMEN

Glycogen storage disease type Ib (GSD-Ib) is a rare inborn error of glycogen metabolism uniquely associated with neutropenia and neutrophil dysfunction, causing severe infections, inflammatory bowel disease (IBD), and impaired wound healing. Recently, kidney sodium-glucose co-transporter-2 (SGLT2) inhibitors such as empagliflozin known to reduce plasma levels of 1,5-anhydroglucitol (1,5-AG) and its toxic derivatives in neutrophils, have been described as a new treatment option in case reports of patients with GSD-Ib from Europe and Asia. We report our experience with an 11-year-old girl with GSD-Ib presenting with short fasting hypoglycemia, neutropenia with neutrophil dysfunction, recurrent infections, suboptimal growth, iron-deficiency anemia, and IBD. Treatment with daily empagliflozin improved neutrophil counts and function with a significant reduction in G-CSF needs. Significant improvement in IBD has led to weight gain with improved nutritional markers and improved fasting tolerance. Reduction of maximum empagliflozin dose was needed due to arthralgia. No other significant side effects of empagliflozin were observed. This report uniquely highlights the novel use of untargeted metabolomics profiling for monitoring plasma levels of 1,5-AG to assess empagliflozin dose responsiveness and guide dietary management and G-CSF therapy. Clinical improvement correlated to rapid normalization of 1,5-AG levels in plasma sustained after dose reduction. In conclusion, empagliflozin appeared to be a safe treatment option for GSD-Ib-associated neutropenia and neutrophil dysfunction. Global untargeted metabolomics is an efficient method to assess biochemical responsiveness to treatment.

10.
J Pediatr Gastroenterol Nutr ; 75(1): 64-69, 2022 07 01.
Artículo en Inglés | MEDLINE | ID: mdl-35622080

RESUMEN

BACKGROUND: Research on the utilization and effectiveness of antitumor necrosis factor (TNF) biologics in children with very early onset inflammatory bowel disease (VEOIBD) is urgently needed. Here we describe anti-TNF use and durability in a multicenter cohort. METHODS: We performed a retrospective cohort study of patients diagnosed with VEOIBD (<6 years) between 2008 and 2013 at 25 North American centers. We performed chart abstraction at diagnosis and 1, 3, and 5 years after diagnosis. We examined the rate of initiation and durability of infliximab and adalimumab and evaluated associations between treatment durability and the following covariates with multivariate Cox proportional hazard regression: age at diagnosis, sex, disease duration, disease classification, and presence of combined immunomodulatory treatment versus monotherapy. RESULTS: Of 294 children with VEOIBD, 120 initiated treatment with anti-TNF therapy and 101 had follow-up data recorded [50% Crohn disease (CD), 31% ulcerative colitis (UC), and 19% IBD unclassified (IBD-U)]. The cumulative probability of anti-TNF treatment was 15% at 1 year, 30% at 3 years, and 45% at 5 years from diagnosis; 56 (55%) were treated between 0 and 6 years old. Anti-TNF durability was 90% at 1 year, 75% at 3 years, and 55% at 5 years. The most common reason for discontinuation of anti-TNF were loss of response in 24 (57%) children. Children with UC/IBD-U had lower durability than those with CD (hazard ratio [HR] 0.17; 95% confidence interval [CI], 0.06-0.51; P = 0.001). CONCLUSIONS: Utilization and durability of anti-TNF in VEOIBD is relatively high and comparable with older children. Having Crohn disease (compared with UC/IBD-U) is associated with greater durability.


Asunto(s)
Productos Biológicos , Colitis Ulcerosa , Enfermedad de Crohn , Enfermedades Inflamatorias del Intestino , Adalimumab/uso terapéutico , Adolescente , Productos Biológicos/uso terapéutico , Niño , Preescolar , Estudios de Cohortes , Colitis Ulcerosa/tratamiento farmacológico , Enfermedad de Crohn/tratamiento farmacológico , Humanos , Lactante , Recién Nacido , Enfermedades Inflamatorias del Intestino/tratamiento farmacológico , Infliximab/uso terapéutico , Necrosis , Estudios Retrospectivos , Inhibidores del Factor de Necrosis Tumoral , Factor de Necrosis Tumoral alfa
11.
IEEE Trans Image Process ; 30: 9220-9230, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34735343

RESUMEN

In this paper, we propose a novel generative framework which uses Generative Adversarial Networks (GANs) to generate features that provide robustness for object detection on reduced-quality images. The proposed GAN-based Detection of Objects (GAN-DO) framework is not restricted to any particular architecture and can be generalized to several deep neural network (DNN) based architectures. The resulting deep neural network maintains the exact architecture as the selected baseline model without adding to the model parameter complexity or inference speed. We first evaluate the effect of image quality on both object classification and object bounding box regression. We then test the models resulting from our proposed GAN-DO framework, using two state-of-the-art object detection architectures as the baseline models. We also evaluate the effect of the number of re-trained parameters in the generator of GAN-DO on the accuracy of the final trained model. Performance results provided using GAN-DO on object detection datasets establish an improved robustness to varying image quality and a higher mAP compared to the existing approaches.

12.
J Pediatr Gastroenterol Nutr ; 73(3): 363-366, 2021 09 01.
Artículo en Inglés | MEDLINE | ID: mdl-34173793

RESUMEN

ABSTRACT: Understanding coronavirus disease 2019 (COVID-19) in pediatric inflammatory bowel disease (PIBD) is important. We describe a single-center cohort of COVID-19 PIBD patients where seroconversion against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was examined.Immunosuppressed PIBD patients at Texas Children's Hospital who tested positive for SARS-CoV-2 by nasopharyngeal reverse transcriptase polymerase chain reaction were included in the study. The clinical course of IBD, concurrent medications, COVID-19 related symptoms, SARS-CoV-2 testing date, and SARS-CoV-2 immunoglobulin G (IgG) antibody testing date and result were examined. Of 14 SARS-CoV-2 positive PIBD patients, 12 were tested for qualitative anti-SARS-CoV-2 IgG (seven with transient COVID-19 symptoms, five asymptomatic). All symptomatic (7/7) and 60% of asymptomatic (3/5) patients seroconverted. No patients required hospitalization attributed to COVID-19.High rates of COVID-19 seroconversion occurred in immunosuppressed and symptomatic PIBD patients. More research to evaluate the significance of COVID-19 seroconversion is needed.


Asunto(s)
COVID-19 , Enfermedades Inflamatorias del Intestino , Anticuerpos Antivirales , Prueba de COVID-19 , Niño , Humanos , SARS-CoV-2 , Seroconversión
13.
Inflamm Bowel Dis ; 27(3): 295-302, 2021 02 16.
Artículo en Inglés | MEDLINE | ID: mdl-32386060

RESUMEN

BACKGROUND: The incidence of very early onset inflammatory bowel disease (VEOIBD) is increasing, yet the phenotype and natural history of VEOIBD are not well described. METHODS: We performed a retrospective cohort study of patients diagnosed with VEOIBD (6 years of age and younger) between 2008 and 2013 at 25 North American centers. Eligible patients at each center were randomly selected for chart review. We abstracted data at diagnosis and at 1, 3, and 5 years after diagnosis. We compared the clinical features and outcomes with VEOIBD diagnosed younger than 3 years of age with children diagnosed with VEOIBD at age 3 to 6 years. RESULTS: The study population included 269 children (105 [39%] Crohn's disease, 106 [39%] ulcerative colitis, and 58 [22%] IBD unclassified). The median age of diagnosis was 4.2 years (interquartile range 2.9-5.2). Most (94%) Crohn's disease patients had inflammatory disease behavior (B1). Isolated colitis (L2) was the most common disease location (70% of children diagnosed younger than 3 years vs 43% of children diagnosed 3 years and older; P = 0.10). By the end of follow-up, stricturing/penetrating occurred in 7 (6.6%) children. The risk of any bowel surgery in Crohn's disease was 3% by 1 year, 12% by 3 years, and 15% by 5 years and did not differ by age at diagnosis. Most ulcerative colitis patients had pancolitis (57% of children diagnosed younger than 3 years vs 45% of children diagnosed 3 years and older; P = 0.18). The risk of colectomy in ulcerative colitis/IBD unclassified was 0% by 1 year, 3% by 3 years, and 14% by 5 years and did not differ by age of diagnosis. CONCLUSIONS: Very early onset inflammatory bowel disease has a distinct phenotype with predominantly colonic involvement and infrequent stricturing/penetrating disease. The cumulative risk of bowel surgery in children with VEOIBD was approximately 14%-15% by 5 years. These data can be used to provide anticipatory guidance in this emerging patient population.


Asunto(s)
Colitis Ulcerosa , Enfermedad de Crohn , Niño , Preescolar , Enfermedad Crónica , Colectomía , Colitis Ulcerosa/epidemiología , Constricción Patológica , Enfermedad de Crohn/epidemiología , Humanos , América del Norte/epidemiología , Estudios Retrospectivos
14.
J Pediatr Surg ; 55(9): 1815-1823, 2020 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-32087936

RESUMEN

BACKGROUND/PURPOSE: Clinical outcomes in pediatric ulcerative colitis (UC) in the era of biologic agents are poorly defined. We aimed to describe risk factors for colectomy in pediatric UC in the era of infliximab therapy. METHODS: We reviewed 217 pediatric patients at Texas Children's Hospital with newly diagnosed UC between 2003 and 2015; 117 had a minimum of 5 years of follow-up. Extent of disease at diagnosis, medication exposure, the presence of extraintestinal manifestations (EIMs), and need for surgery were noted. RESULTS: Average length of follow up was 5.02 ±â€¯2.27 years. Forty-two percent presented with pancolitis. Infliximab was used in 39%, immunomodulators in 65%, and steroids in 89% of patients. EIMs occurred in 24.9% of patients. The cumulative rate of colectomy was 12.9% at 5 years. Children presenting as E2 (Paris Classification) and children prescribed oral steroid monotherapy at diagnosis progressed to surgery faster than any other group. Of the children who received infliximab, females and children less than 5 years old were less likely to respond to therapy. CONCLUSIONS: The natural course of pediatric UC remains aggressive despite the addition of infliximab to the standard of care and suggests a need for early aggressive clinical intervention. LEVEL-OF-EVIDENCE RATING: Level IV.


Asunto(s)
Colectomía/estadística & datos numéricos , Colitis Ulcerosa , Adolescente , Niño , Colitis Ulcerosa/epidemiología , Colitis Ulcerosa/cirugía , Progresión de la Enfermedad , Estudios de Seguimiento , Humanos , Factores de Riesgo
15.
IEEE Trans Image Process ; 28(12): 6022-6034, 2019 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-31251188

RESUMEN

In recent years, the widespread use of deep neural networks (DNNs) has facilitated great improvements in performance for computer vision tasks like image classification and object recognition. In most realistic computer vision applications, an input image undergoes some form of image distortion such as blur and additive noise during image acquisition or transmission. Deep networks trained on pristine images perform poorly when tested on such distortions. In this paper, we evaluate the effect of image distortions like Gaussian blur and additive noise on the activations of pre-trained convolutional filters. We propose a metric to identify the most noise susceptible convolutional filters and rank them in order of the highest gain in classification accuracy upon correction. In our proposed approach called DeepCorrect, we apply small stacks of convolutional layers with residual connections at the output of these ranked filters and train them to correct the worst distortion affected filter activations, while leaving the rest of the pre-trained filter outputs in the network unchanged. Performance results show that applying DeepCorrect models for common vision tasks like image classification (ImageNet), object recognition (Caltech-101, Caltech-256), and scene classification (SUN-397), significantly improves the robustness of DNNs against distorted images and outperforms other alternative approaches.

16.
Artículo en Inglés | MEDLINE | ID: mdl-30010576

RESUMEN

We study deep neural networks for classification of images with quality distortions. Deep network performance on poor quality images can be greatly improved if the network is fine-tuned with distorted data. However, it is difficult for a single fine-tuned network to perform well across multiple distortion types. We propose a mixture of experts based ensemble method, MixQualNet, that is robust to multiple different types of distortions. The "experts" in our model are trained on a particular type of distortion. The output of the model is a weighted sum of the expert models, where the weights are determined by a separate gating network. The gating network is trained to predict weights for a particular distortion type and level. During testing, the network is blind to the distortion level and type, yet can still assign appropriate weights to the expert models. In order to reduce the computational complexity, we introduce weight sharing into the MixQualNet. We utilize the TreeNet weight sharing architecture as well as introduce the Inverted TreeNet architecture. While both weight sharing architectures reduce memory requirements, our proposed Inverted TreeNet also achieves improved accuracy.

17.
Artículo en Inglés | MEDLINE | ID: mdl-29993885

RESUMEN

Visual saliency models have recently begun to incorporate deep learning to achieve predictive capacity much greater than previous unsupervised methods. However, most existing models predict saliency without explicit knowledge of global scene semantic information. We propose a model (MxSalNet) that incorporates global scene semantic information in addition to local information gathered by a convolutional neural network. Our model is formulated as a mixture of experts. Each expert network is trained to predict saliency for a set of closely related images. The final saliency map is computed as a weighted mixture of the expert networks' output, with weights determined by a separate gating network. This gating network is guided by global scene information to predict weights. The expert networks and the gating network are trained simultaneously in an end-toend manner. We show that our mixture formulation leads to improvement in performance over an otherwise identical nonmixture model that does not incorporate global scene information. Additionally, we show that our model achieves better performance than several other visual saliency models.

18.
J Mol Biochem ; 7(1): 41-47, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-31032235

RESUMEN

Lactase deficiency can lead to significant symptoms in the pediatric population. To date, few studies have examined the prevalence of enzyme testing-based lactase and other disaccharidase deficiencies (DDs) in pediatric patients undergoing upper endoscopic evaluation. The primary objective of this study was to determine the prevalence of selective lactase and other DDs amongst a large cohort of pediatric patients with and without inflammatory bowel disease (IBD: Crohn's disease and ulcerative colitis) via a chart review of 739 patients who underwent esophago-gastro-dudenoscopy EGD between April 2010 and August 2016. We identified 560 pediatric patients (ages 1-18 years) who underwent mucosal enzyme testing at the time of their EGD. The overall rate of lactase deficiency (LD) was 39%. LD positively correlated with age (p=0.00017), but there was no significant difference between age matched IBD and non-IBD patients (45% vs. 42% p=0.68). Four patients (0.17%) were found to have selective maltase deficiency. No selective sucrase or palatinase deficiency was identified. Statistically significant differences occurred in lactase deficiency amongst patients of different races. In conclusion, lactase deficiency is a relatively common finding in children undergoing EGD though at no increased rate amongst the IBD patient population. Disaccharidase testing should be considered in pediatric patients undergoing EGD.

19.
IEEE Trans Image Process ; 25(8): 3852-61, 2016 08.
Artículo en Inglés | MEDLINE | ID: mdl-27295671

RESUMEN

With the increased focus on visual attention (VA) in the last decade, a large number of computational visual saliency methods have been developed over the past few years. These models are traditionally evaluated by using performance evaluation metrics that quantify the match between predicted saliency and fixation data obtained from eye-tracking experiments on human observers. Though a considerable number of such metrics have been proposed in the literature, there are notable problems in them. In this paper, we discuss shortcomings in the existing metrics through illustrative examples and propose a new metric that uses local weights based on fixation density, which overcomes these flaws. To compare the performance of our proposed metric at assessing the quality of saliency prediction with other existing metrics, we construct a ground-truth subjective database in which saliency maps obtained from 17 different VA models are evaluated by 16 human observers on a five-point categorical scale in terms of their visual resemblance with corresponding ground-truth fixation density maps obtained from eye-tracking data. The metrics are evaluated by correlating metric scores with the human subjective ratings. The correlation results show that the proposed evaluation metric outperforms all other popular existing metrics. In addition, the constructed database and corresponding subjective ratings provide an insight into which of the existing metrics and future metrics are better at estimating the quality of saliency prediction and can be used as a benchmark.


Asunto(s)
Algoritmos , Bases de Datos Factuales , Fijación Ocular , Modelos Teóricos , Atención , Humanos
20.
Worldviews Evid Based Nurs ; 13(3): 216-23, 2016 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-26646555

RESUMEN

BACKGROUND: The well-documented increases in obesity and unhealthy dietary practices substantiate the need for evidence-based tools that can help people improve their dietary habits. The current spread of mobile phone-embedded cameras offers new opportunities for recording food intake. Moreover, the act of taking pictures of food consumed may enhance visual consciousness of food choice and quantity. The present study aimed to assess the effect of using cell phone pictures to record food intake on energy intake and food choice in college students. The effectiveness and acceptability of cell phone picture-based diet recording also was assessed. METHODS: A repeated measures crossover design was used. One group of participants entered their food intake online during 3 days based on their memory, although a second group recorded their food intake using cell phone pictures as their reference. Participants then crossed over to complete 3 more days of diet recording using the alternate method. Focus groups were conducted to obtain feedback on the effectiveness and acceptability of cell phone picture-based diet recording. RESULTS: Intake of meat and vegetable servings were significantly higher in the memory period compared with the cell phone period, regardless of the order. Results from the focus group indicated a positive attitude toward the use of cell phone pictures in recording food intake and an increased awareness of food choice and portion size. LINKING EVIDENCE TO ACTION: Cell phone pictures may be an easy, relevant, and accessible method of diet self-monitoring when aiming at dietary changes. Future trials should combine this technique with healthy eating education.


Asunto(s)
Teléfono Celular , Registros de Dieta , Ingestión de Alimentos , Fotograbar/métodos , Femenino , Grupos Focales , Humanos , Masculino , Fotograbar/instrumentación , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA